+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Neoadjuvant chemotherapy with a combination of docetaxel, cisplatin, fluorouracil, and leucovorin in nonresectable advanced gastric cancer: a short communication



Neoadjuvant chemotherapy with a combination of docetaxel, cisplatin, fluorouracil, and leucovorin in nonresectable advanced gastric cancer: a short communication



Medical Oncology 27(4): 1089-1095



The aim of this study was to evaluate the efficacy and toxicity of docetaxel (TAX), cisplatin (CDDP), and fluorouracil (5-FU) plus leucovorin (CF) as the neoadjuvant chemotherapy (NACT) regimens in the treatment of nonresectable advanced gastric cancer. Twelve patients with nonresectable advanced gastric cancer were treated with NACT regimens consisted of docetaxel, cisplatin, fluorouracil, plus leucovorin before operation. Nine of the 12 patients were downstaged and 8 were radically operated after the end of the NACT. The overall response rate was 75% with 8.3% complete response and 66.7% partial response, and the ascites disappeared in 63.6%. The most common toxicities were bone marrow suppression, nausea, vomiting, alopecia, and heptoses. The toxicities were recoverable after symptomatic treatment. The results confirmed that the combination of docetaxel, cisplatin, fluorouracil plus leucovorin (CF) is a very effective and well-tolerated regimen as NACT for the patients with nonresectable advanced gastric cancer.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054567033

Download citation: RISBibTeXText

PMID: 19885749

DOI: 10.1007/s12032-009-9340-7


Related references

Treatment of Borrmann type IV gastric cancer with a neoadjuvant chemotherapy combination of docetaxel, cisplatin and 5-fluorouracil/leucovorin. Journal of International Medical Research 39(6): 2096-2102, 2012

The combination of docetaxel and cisplatin plus fluorouracil as neoadjuvant chemotherapy in the treatment of T4 stage gastric cancer. Surgical Oncology 19(1): 1-3, 2008

Neoadjuvant chemotherapy in advanced gastric cancer with non-curative factors: a Phase II study with 5-fluorouracil, leucovorin, and cisplatin. Gastric Cancer 2(1): 57-63, 2002

The efficacy of docetaxel and cisplatin combination chemotherapy for the treatment of advanced gastric cancer after failing to 5-fluorouracil based chemotherapy. Cancer Research and Treatment 36(6): 367-371, 2004

A case of advanced gastric cancer showing pathological CR after neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 combination. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 38(10): 1687-1690, 2011

A pilot study of cisplatin, irinotecan, leucovorin and 5-fluorouracil (PILF) combination chemotherapy for advanced gastric cancer. Cancer Research and Treatment 38(3): 121-125, 2006

Combination docetaxel (Taxotere), fluorouracil, and leucovorin (TFL), as first-line chemotherapy in advanced gastric cancer: a Hellenic Cooperative Oncology Group phase II study. Gastric Cancer 9(1): 26-31, 2006

Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer. Annals of Oncology 19(4): 729-733, 2007

Docetaxel-cisplatin (DC) versus 5-fluorouracil-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase III study. Journal of Clinical Oncology 26(15_suppl): 4512-4512, 2016

Docetaxel-cisplatin (DC) versus 5-fluorouracil-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary safety results of a phase III study. Journal of Clinical Oncology 23(16_suppl): 4045-4045, 2016

Randomized trial of neoadjuvant chemotherapy with cisplatin plus 5-fluorouracil, with or without leucovorin, in locally advanced head and neck cancer. Annals of Oncology 8(7): 713-714, 1997

Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. Journal of Clinical Oncology 25(22): 3217-3223, 2007

A randomized, comparative study of combination chemotherapies in advanced gastric cancer: 5-fluorouracil and cisplatin (FP) versus 5-fluorouracil, cisplatin, and 4'-epirubicin (FPEPIR). Kyoto Research Group for Chemotherapy of Gastric Cancer (KRGCGC). Anticancer Research 12(6b): 1983-1988, 1992

A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker. Cancer ChemoTherapy and Pharmacology 71(3): 789-797, 2013

Clinical study of cisplatin hyperthermic intraperitoneal perfusion chemotherapy in combination with docetaxel, 5-flourouracil and leucovorin intravenous chemotherapy for the treatment of advanced-stage gastric carcinoma. Hepato-Gastroenterology 60(125): 989-994, 2014